Last updated: August 3, 2023
Sponsor: Xiangya Hospital of Central South University
Overall Status: Active - Recruiting
Phase
4
Condition
Stroke
Epilepsy
Cerebral Ischemia
Treatment
idebenone 30 mg for 14 days
idebenone 30 mg for 3 months
Clinical Study ID
NCT05987397
202306124
Ages 18-80 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patients admitted to hospital within 24 hours of stroke symptoms and diagnosed withstroke (including cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage,intracranial venous sinus thrombosis, etc.) after relevant examinations;
- Able to cooperate with the inspection;
- Sign the informed consent form.
Exclusion
Exclusion Criteria:
- History of epilepsy before stroke;
- A history of serious comorbidities that may lead to seizures (including malignanttumors, specific autoimmune diseases, severe electrolyte abnormalities, end-stagerenal disease, and severe head trauma);
- Secondary stroke caused by head trauma or surgery;
- Other patients that the researchers think need to be excluded.
Study Design
Total Participants: 2700
Treatment Group(s): 2
Primary Treatment: idebenone 30 mg for 14 days
Phase: 4
Study Start date:
July 05, 2023
Estimated Completion Date:
December 31, 2025
Connect with a study center
Xiangya Hospital, Central South University
Changsha, Hunan 410008
ChinaActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.